Europe Microvillus Inclusion Disease Market Size, Trends, Growth Report 2033

Europe Microvillus Inclusion Disease Market

Market Size in USD Million

CAGR : 3.80 %

Bar chart comparing the Europe Microvillus Inclusion Disease Market size in 2025 - 492.79 and 2033 - 666.68, highlighting the projected market growth.

USD 492.79 Million USD 666.68 Million 2025 2033

Forecast Period	2026 - 2033
Market Size (Base Year)	USD 492.79 Million
Market Size (Forecast Year)	USD 666.68 Million
CAGR	3.80 %
Major Markets Players	Baxter International Inc. (U.S.) Fresenius SE & Co. KGaA (Germany) B. Braun SE (Germany) Nestlé Health Science (Switzerland) Nutricia (Danone Group) (Netherlands)

Europe Microvillus Inclusion Disease Market Overview

The Europe Microvillus Inclusion Disease Market size was valued at USD 666.68 million by 2033 from USD 492.79 million in 2025, growing at a CAGR of 3.8% during the forecast period. The Europe Microvillus Inclusion Disease Market is experiencing steady growth, driven by the increasing prevalence of rare congenital intestinal disorders, rising awareness regarding early diagnosis, and the growing demand for advanced nutritional support therapies, parenteral nutrition solutions, and specialized paediatric care.
Increasing investments in rare disease research, advancements in genetic testing technologies, and expanding healthcare infrastructure across developed and emerging economies are significantly supporting market growth, along with the rising focus on improving long-term disease management and patient survival outcomes worldwide.

Market Size & Forecast

Market Value (2025): USD 492.79 million
Expected Market Value (2033): USD 666.68 million
Forecast CAGR (2026–2033): 3.8%
Leading Country in 2025: Germany
Fastest Growing Country: Netherlands

Key Market Trends & Insights

Germany dominated the Europe microvillus inclusion disease (MVID) market primarily with a market share of 16.21% in 2025, due to its advanced healthcare infrastructure, strong capabilities in genetic diagnostics, increasing focus on rare disease management, and high adoption of specialized pediatric treatment approaches.
The Netherlands is expected to be the fastest-growing country in the Europe Microvillus Inclusion Disease (MVID) Market with a CAGR of 4.5% due to the expanding healthcare sector, growing awareness of rare genetic disorders, increasing access to molecular diagnostic technologies, and rising investments in pediatric healthcare services.
In 2026, the Early-Onset (Congenital) MVID segment is expected to dominate the market with a market share of 34.44%, due to the fact that most diagnosed cases manifest during infancy, requiring early diagnosis, intensive nutritional management, and long-term clinical care.
Intravenous (IV) accounts for 62.60% of the market, due to severe intestinal malabsorption and inability to absorb nutrients orally. The dominance of IV administration is further supported by its ability to ensure precise nutrient delivery, maintain fluid and electrolyte balance, and support growth and survival in pediatric patients. Increasing use of home-based IV nutrition programs, advancements in catheter technology, and improved infection management protocols are also contributing to its widespread adoption.
The subcutaneous segment is the fastest-growing category, with a CAGR of 4.2%, driven by increasing adoption of less invasive and more patient-friendly delivery methods for supportive therapies in rare disease management, improvements in drug formulation technologies that enable subcutaneous absorption of specialized nutrients and biologics, and growing interest in home-based care models that reduce hospital dependency.

Europe Report Scope and Europe Microvillus Inclusion Disease Market Segmentation

Attributes	Microvillus Inclusion Disease Key Market Insights
Segments Covered	By Disease Type / Clinical Presentation- Early-Onset (Congenital) MVID, Genetic Subtypes, Non-Syndromic MVID, Syndromic MVID, and Late-Onset / Atypical MVID By Treatment Type- Nutritional Support, Surgical & Advanced Interventions, Pharmacological Management, Emerging & Pipeline Therapies By Route of Administration- Intravenous (IV), Oral, Subcutaneous, Enteral, and Others By Diagnosis Type- Genetic Testing, Definitive Diagnostics, Laboratory Testing, Imaging & Support Diagnostics By End User- Hospitals, Pediatric Specialty Clinics, Home Healthcare Settings (TPN Administration), Transplant Centers, Research Institutes & Academic Centers, Others By Patient Demographics- Neonates, Infants, Pediatric (Long-Term Survivors) By Distribution Channel- Hospital Pharmacies, Specialty Pharmacies, Direct Procurement, Online Pharmacies, and Others
Countries Covered	Europe Germany France U.K. Netherlands Switzerland Belgium Russia Italy Spain Turkey Sweden Denmark Norway Finland Rest of Europe
Key Market Players	Baxter International Inc. (U.S.) Fresenius SE & Co. KGaA (Germany) B. Braun SE (Germany) Nestlé Health Science (Switzerland) Nutricia (Danone Group) (Netherlands) Ipsen Pharma (France) Gedeon Richter Plc. (Hungary) Abbott Laboratories (U.S.) Novartis AG (Switzerland) Chiesi Farmaceutici S.p.A. (Italy) Laboratoire Aguettant (France) Sichuan Kelun Pharmaceutical Co., Ltd. (China) Kate Farms (U.S.) Hexagon Nutrition Ltd. (India) Pfizer Inc. (U.S.) Jaguar Health (U.S.) Sun Pharmaceutical Industries Ltd. (India) Luoxin Pharmaceuticals Group Stock Co., Ltd. (China) Ajinomoto Cambrooke, Inc. (U.S.) Teva Pharmaceutical Industries Ltd. (Israel) Phebra Pty Ltd (Australia) Nutrisens Medical Italia (Italy) Otsuka Pharmaceutical India Private Limited (Japan) Aculife Healthcare Pvt. Ltd. (India) Functional Formularies (U.S.) Kenvue (U.S.) Novus Lifesciences Pvt. Ltd. (India) USV Private Limited (India) Pentagon Labs Ltd. (India) Oscar Remedies Private Limited (India) Pristine Organics (India) Emyris (India)
Market Opportunities	Emergence of gene therapy targeting MYO5B mutations Advancements in organoid-based and stem cell therapies
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Trend: Advancements in Genetic Diagnostics and Personalized Treatment Approaches

The global microvillus inclusion disease (MVID) market is witnessing significant advancements driven by the integration of sophisticated genetic diagnostic technologies and personalised treatment strategies. Whole exome sequencing (WES), next-generation sequencing (NGS), and molecular diagnostic platforms are increasingly being adopted to identify MYO5B gene mutations responsible for MVID, enabling earlier diagnosis, improved diagnostic accuracy, and timely clinical intervention in infants and paediatric patients. Early genetic confirmation is facilitating better disease management while reducing diagnostic delays commonly associated with rare congenital disorders.

In parallel, personalised treatment approaches, including customised parenteral nutrition regimens, precision medicine strategies, targeted supportive therapies, and multidisciplinary care models, are improving patient outcomes and quality of life. Advances in intestinal rehabilitation programmes, enhanced parenteral nutrition formulations, specialised paediatric monitoring systems, and digital integration of electronic health records (EHRs), rare disease registries, and genetic research databases are supporting data-driven clinical decision-making, standardised patient management, and accelerated research activities. These developments are collectively transforming the clinical management landscape and driving innovation in the global MVID market.

Key Market Driver: Advancements in Genetic Diagnostics and Next-Generation Sequencing

Advancements in genetic diagnostics and next-generation sequencing (NGS) technologies are a primary driver of the global Europe Microvillus Inclusion Disease Market. These technologies enable accurate identification of disease-causing mutations, particularly in the MYO5B gene, allowing clinicians to diagnose MVID at an early stage and initiate timely clinical interventions. Improved diagnostic accuracy supports better patient management, genetic counselling, and the development of personalised therapeutic strategies while reducing the likelihood of misdiagnosis in this ultra-rare disorder. As healthcare systems continue to adopt advanced genomic technologies and precision medicine approaches, the demand for specialised diagnostic services and targeted treatment solutions is expected to increase.

In 2023, according to an article published by Elsevier Inc., researchers developed a novel Myo5b(G519R) mouse model using one-step two-cell embryo microinjection and Cre/loxP technology. This model accurately replicates patient-specific MYO5B mutations, providing valuable insights into disease mechanisms and supporting the development of targeted therapies, thereby contributing to the growth of the global MVID market.

Key Market Restraint/Challenge: Extremely Low Disease Prevalence

The extremely low prevalence of microvillus inclusion disease remains one of the most significant challenges limiting market growth. As an ultra-rare inherited disorder, MVID affects a very small patient population globally, reducing the commercial viability of developing novel diagnostic tools and therapeutic products. The limited number of patients also creates substantial challenges in conducting clinical trials, recruiting eligible participants, and generating robust clinical evidence required for regulatory approvals. Furthermore, limited epidemiological data, low disease awareness, and the absence of standardised treatment guidelines hinder widespread adoption of advanced therapies. These factors collectively restrict research investments, delay product development, and constrain overall market expansion.

In April 2026, according to an article published by BioSpace, ongoing clinical development programmes for MVID continue to explore therapies aimed at reducing dependence on parenteral nutrition while pursuing expedited regulatory pathways, including Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). However, the limited patient population remains a major barrier to large-scale clinical development, funding, and commercialisation, thereby restraining market growth.

Key Market Opportunity: Emergence of Gene Therapy Targeting MYO5B Mutations

The emergence of gene therapy targeting MYO5B mutations represents a significant opportunity for the global Europe Microvillus Inclusion Disease Market. Since mutations in the MYO5B gene are the primary cause of MVID, advances in gene editing technologies, viral vector platforms, and precision medicine are creating the potential to treat the disease at its genetic source rather than relying solely on supportive care. Ongoing research into gene replacement and gene correction therapies has the potential to reduce long-term dependence on parenteral nutrition, improve intestinal function, and decrease the need for intestinal transplantation.

Growing investments in rare disease research, favourable orphan drug incentives, increasing collaborations between biotechnology companies and academic institutions, and advancements in genomic medicine are accelerating the development of innovative therapeutic candidates. As more gene therapy programmes progress through preclinical and clinical development, they are expected to expand treatment options and create substantial long-term growth opportunities for the MVID market.

In March 2025, according to BioSpace, Entero Therapeutics, Inc. received positive feedback from the U.S. Food and Drug Administration (FDA) regarding the clinical development pathway for its investigational therapy for microvillus inclusion disease. Alongside continued progress in gene therapy research targeting MYO5B mutations, these developments are expected to strengthen the future treatment landscape and create significant opportunities for market growth.

Europe Microvillus Inclusion Disease Market is categorized into seven notable segments which are based on disease type / clinical presentation, treatment type, route of administration, diagnosis type, end user, patient demographics, and distribution channel.

By Disease Type

On the basis of disease type / clinical presentation, the Europe Microvillus Inclusion Disease Market is segmented into early-onset (congenital) MVID, genetic subtypes, non-syndromic MVID, syndromic MVID, late-onset / atypical MVID. In 2026, the early-onset (congenital) MVID segment is expected to dominate the Europe Microvillus Inclusion Disease Market with 34.54% market share due to the high prevalence of severe neonatal presentations requiring immediate and long-term medical intervention. Most diagnosed cases occur within the first days or months of life, leading to early dependence on total parenteral nutrition, intensive hospitalization, and specialized pediatric care. Increasing awareness among neonatologists, improvements in genetic diagnostics, and rising adoption of advanced supportive therapies are further contributing to the dominance of this segment in the Europe market.

The syndromic MVID segment is expected to be fastest growing with a CAGR of 4.3%, due to increasing recognition of complex genetic syndromes associated with MVID, advancements in molecular diagnostic techniques, and improved identification of patients presenting with extraintestinal manifestations. Growing research into rare genetic disorders, enhanced access to genetic screening programs, and the need for comprehensive multidisciplinary care approaches are further contributing to the growth of this segment.

By Treatment Type

On the basis of treatment type, the Europe Microvillus Inclusion Disease Market is segmented into nutritional support, surgical & advanced interventions, pharmacological management, and emerging & pipeline therapies. In 2026, the nutritional support segment is expected to dominate the market with 69.32% market share due to the critical dependence of microvillus inclusion disease patients on long-term nutritional management for survival. Since the disease severely impairs intestinal absorption, most patients require continuous total parenteral nutrition (TPN) and specialized nutritional formulations from infancy. The absence of widely approved curative therapies, increasing use of home-based TPN systems, and growing focus on improving pediatric nutritional outcomes are further driving demand for nutritional support therapies. Additionally, advancements in customized nutrient formulations and supportive care infrastructure continue to strengthen segment dominance in Europe.

The emerging & pipeline therapies segment is expected to be fastest growing with a CAGR of 4.2%, due to increasing investments in rare disease research, ongoing development of gene-based and targeted therapies, and growing efforts to address the underlying genetic causes of MVID. Advancements in precision medicine, expanding clinical research activities, and the demand for more effective long-term treatment options beyond supportive nutritional care are further driving the growth of this segment.

By Route of Administration

On the basis of route of administration, the Europe Microvillus Inclusion Disease Market is segmented into intravenous (IV), oral, subcutaneous, enteral, and others. In 2026, the subcutaneous segment is expected to dominate the market with 62.64% market share due to the increasing use of subcutaneous anti-secretory and supportive therapies that provide improved convenience, reduced hospitalization requirements, and enhanced long-term disease management. Several medications used in microvillus inclusion disease management, including octreotide-based therapies, are commonly administered through the subcutaneous route for better patient compliance and sustained therapeutic effects. Growing preference for home-based care, reduced risk of intravenous complications, and advancements in self-administration delivery systems are further supporting the dominance of the subcutaneous segment in the Europe market.

The subcutaneous segment is expected to be fastest growing with a CAGR of 4.2%, due to the increasing development of biologic and targeted therapies designed for convenient administration and improved patient compliance. The subcutaneous route offers advantages such as reduced hospital visits, ease of self-administration, and enhanced treatment accessibility, making it an attractive option for long-term management of rare genetic disorders, including emerging therapeutic approaches for MVID.

By Diagnosis Type

On the basis of diagnosis type, Europe Microvillus Inclusion Disease Market is segmented into genetic testing, definitive diagnostics, laboratory testing, and imaging & support diagnostics. In 2026, the genetic testing segment is expected to dominate the Europe Microvillus Inclusion Disease Market with 40.11% market share due to the growing adoption of advanced molecular diagnostic technologies for early and accurate disease identification. Increasing awareness regarding MYO5B and other associated genetic mutations has accelerated the use of postnatal and prenatal genetic screening in high-risk populations. Genetic testing enables faster confirmation of diagnosis compared to invasive procedures, supporting timely clinical intervention and personalized treatment planning. Additionally, expanding availability of next-generation sequencing technologies and rising demand for carrier screening are further strengthening the dominance of this segment.

The genetic testing segment is expected to register the highest CAGR of 4.4% in the forecast period.

The genetic testing segment is expected to register the highest CAGR of 4.4% in the forecast period. As genetic testing enables faster confirmation of diagnosis compared to invasive procedures, supporting timely clinical intervention and personalized treatment planning. Additionally, expanding availability of next-generation sequencing technologies and rising demand for carrier screening are further strengthening the dominance of this segment.

By End User

On the basis of end user, Europe Microvillus Inclusion Disease Market is segmented into hospitals, pediatric specialty clinics, home healthcare settings (TPN administration), transplant centers, research institutes & academic centers, and others. In 2026, the hospitals segment is expected to dominate the Europe Microvillus Inclusion Disease Market with 39.42% market share due to the need for intensive multidisciplinary care and continuous clinical monitoring in patients with severe gastrointestinal complications. Most microvillus inclusion disease patients require prolonged hospitalization for total parenteral nutrition administration, electrolyte management, infection control, and neonatal intensive care support. Hospitals also provide access to advanced diagnostic technologies, pediatric gastroenterologists, transplant services, and emergency interventions essential for disease management. Additionally, increasing availability of specialized pediatric care units and improved hospital-based nutritional support infrastructure are further contributing to segment dominance.

The home healthcare settings (TPN administration) segment is expected to be fastest growing with a CAGR of 4.2%, due to the increasing preference for home-based long-term care, advancements in total parenteral nutrition (TPN) delivery systems, and the need to reduce prolonged hospital stays. Improved patient monitoring technologies, enhanced caregiver support programs, and growing efforts to improve quality of life for patients with chronic intestinal failure are further driving the adoption of home healthcare settings.

By Patient Demographics

On the basis of patient demographics, Europe Microvillus Inclusion Disease Market is segmented into neonates, infants, and pediatric (long-term survivors). In 2026, the neonates segment is expected to dominate the Europe Microvillus Inclusion Disease Market with 53.67% market share due to the predominantly congenital nature of the disease, with symptoms typically appearing within the first days of life. Severe neonatal diarrhea, dehydration, malabsorption, and rapid nutritional deterioration often require immediate hospitalization and intensive supportive care. Early diagnosis in neonatal intensive care units, increasing use of genetic testing, and dependence on long-term total parenteral nutrition contribute significantly to healthcare utilization in this population. Additionally, rising awareness among pediatric specialists is supporting earlier detection and management of neonatal cases.

The pediatric (long-term survivors) segment is expected to be fastest growing with a CAGR of 4.2%, due to improvements in early diagnosis, advanced nutritional support therapies, and better long-term disease management strategies that have increased survival rates among affected children. Growing access to specialized pediatric care, multidisciplinary treatment approaches, and ongoing monitoring of nutritional and developmental outcomes are further contributing to the expansion of this segment.

By Distribution Channel

On the basis of distribution channel, the Europe Microvillus Inclusion Disease Market is segmented into hospital pharmacies, specialty pharmacies, direct procurement, online pharmacies, and others. In 2026, the hospital pharmacy segment is expected to dominate the Europe Microvillus Inclusion Disease Market with 43.64% market share due to the high dependence on hospital-based treatment and specialized medication management for critically ill patients. Most therapies used in microvillus inclusion disease, including total parenteral nutrition components, electrolyte replacements, antibiotics, and anti-secretory agents, are administered and monitored within hospital settings. Hospital pharmacies ensure immediate access to complex formulations, sterile nutritional preparations, and emergency supportive medications required for neonatal and pediatric care. Additionally, the growing number of specialized pediatric hospitals and multidisciplinary treatment centers is further strengthening the dominance of this segment.

The online pharmacies segment is expected to be fastest growing with a CAGR of 4.2%, due to due to the increasing adoption of digital healthcare platforms, growing demand for convenient access to specialized nutritional products and medications, and expanding e-commerce penetration in healthcare. Enhanced home delivery services, improved availability of prescription management tools, and the rising preference for remote healthcare support among patients and caregivers are further driving the growth of this segment.

Europe Microvillus Inclusion Disease Market Regional Analysis.

Germany holds the largest market share in the Europe Microvillus Inclusion Disease Market, contributing around 16.21% in 2025. The region benefits from well-established healthcare systems, increasing government support for rare disease management, and rising awareness regarding early diagnosis of congenital intestinal disorders. Growing research activities in precision medicine and genetic diagnostics are supporting improved disease identification and patient management. Furthermore, the presence of specialized pediatric treatment centers and expanding collaboration between research institutes and healthcare providers are enhancing treatment accessibility and improving survival outcomes for patients affected by microvillus inclusion disease across the region.

Netherlands Europe Microvillus Inclusion Disease Market Insight

The Netherlands is the fastest-growing region in the Europe Microvillus Inclusion Disease Market, projected to register a CAGR of 4.5% during the forecast period. Rapid improvements in healthcare infrastructure, increasing healthcare expenditure, and rising awareness regarding rare genetic diseases are driving regional market growth. Expanding access to genetic screening programs, improving neonatal healthcare facilities, and rising government initiatives focused on rare disease management are further accelerating demand for effective diagnosis and supportive treatment solutions across the region.

France Europe Microvillus Inclusion Disease Market Insight

France Europe Microvillus Inclusion Disease Market is supported by a well-developed healthcare infrastructure, strong government initiatives for rare disease management, and increasing awareness of early diagnosis and treatment of congenital gastrointestinal disorders. The country’s emphasis on genetic research, precision medicine, and advanced diagnostic technologies is contributing to improved detection and management of microvillus inclusion disease. Additionally, the presence of specialized pediatric hospitals, dedicated rare disease centers, and active collaboration between research institutions and healthcare providers is enhancing patient access to specialized care and improving long-term clinical outcomes across France

Europe Microvillus Inclusion Disease Market Share

The microvillus inclusion disease industry is primarily led by well-established companies, including:

Baxter International Inc. (U.S.)
Fresenius SE & Co. KGaA (Germany)
B. Braun SE (Germany)
Nestlé Health Science (Switzerland)
Nutricia (Danone Group) (Netherlands)
Ipsen Pharma (France)
Gedeon Richter Plc. (Hungary)
Abbott Laboratories (U.S.)
Novartis AG (Switzerland)
Chiesi Farmaceutici S.p.A. (Italy)
Laboratoire Aguettant (France)
Sichuan Kelun Pharmaceutical Co., Ltd. (China)
Kate Farms (U.S.)
Hexagon Nutrition Ltd. (India)
Pfizer Inc. (U.S.)
Jaguar Health (U.S.)
Sun Pharmaceutical Industries Ltd. (India)
Luoxin Pharmaceuticals Group Stock Co., Ltd. (China)
Ajinomoto Cambrooke, Inc. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Phebra Pty Ltd (Australia)
Nutrisens Medical Italia (Italy)
Otsuka Pharmaceutical India Private Limited (Japan)
Aculife Healthcare Pvt. Ltd. (India)
Functional Formularies (U.S.)
Kenvue (U.S.)
Novus Lifesciences Pvt. Ltd. (India)
USV Private Limited (India)
Pentagon Labs Ltd. (India)
Oscar Remedies Private Limited (India)
Pristine Organics (India)
Emyris (India)

Latest Developments in Europe Microvillus Inclusion Disease Market

In April 2026, Baxter International showcased its latest innovations in surgical care at the AORN Global Surgical Conference & Expo 2026 in New Orleans, highlighting additions to its surgical solutions and patient support portfolio. The company featured new technologies including the AAT XR spine surgical table and the Dynamo Series smart stretcher aimed at improving operating room efficiency and patient handling. These advancements are expected to strengthen Baxter’s market position by enhancing surgical workflow efficiency, improving patient safety outcomes, and supporting broader adoption of its advanced perioperative solutions.
In October 2024, B. Braun Medical Inc. announced plans to increase IV fluid production by 20% at its U.S. facilities to address nationwide shortages and strengthen hospital supply continuity for infusion therapy and nutrition support products. This expansion supports healthcare providers by improving availability of critical IV and clinical nutrition supplies during high-demand periods. It will benefit B. Braun by strengthening its position in the hospital infusion and nutrition market, increasing product availability, and building long-term trust with healthcare providers.
In February 2026, Nestlé Health Science announced the inclusion of its nutritional products under an exceptional reimbursement framework within Portugal’s public health system, allowing eligible products to be partially or fully covered by the National Health Service. This regulatory decision strengthens patient access to clinical nutrition solutions and supports integration of medical nutrition into formal healthcare reimbursement pathways. This will benefit the company by improving product accessibility, expanding prescription-based demand, and reinforcing its position within the reimbursed clinical nutrition market
In May 2024, Danone is investing €70 million in France to expand its Steenvoorde plant for Nutricia oral nutritional supplements. The project boosts capacity for patients with disease-related malnutrition and includes sustainability upgrades like a biomass boiler to reduce emissions and improve efficiency. This investment will strengthen Danone’s medical nutrition capacity, supporting long-term growth in a high-demand healthcare nutrition segment.
In 2025, Abbott expanded it Glucerna nutrition product lines in 2025, introducing improved formulations with enhanced protein content, better taste, and additional product formats such as ready-to-drink shakes and snack-based nutrition options. The expansion is aimed at supporting muscle health, diabetes management, aging populations, and clinical nutrition needs in hospital and home-care settings

SKU-76523

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE MICROVILLUS INCLUSION DISEASE MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTLE ANALYSIS

4.3 PIPELINE ANALYSIS:

4.3.1 INCIDENCE OF MVID BY GENDER

4.3.2 TREATMENT RATE

4.3.3 MORTALITY RATE

4.3.4 DRUG ADHERENCE & THERAPY SWITCH MODEL

4.3.5 PATIENT TREATMENT SUCCESS RATES

4.4 INDUSTRY INSIGHTS:

4.4.1 MICRO AND MACRO ECONOMIC FACTORS

4.4.2 PENETRATION AND GROWTH PROSPECT MAPPING

4.4.3 KEY PRICING STRATEGIES

4.4.4 ANALYSIS AND RECOMMENDATION

4.5 SUPPLY CHAIN RESILIENCE

4.5.1 DIVERSIFICATION OF PHARMACEUTICAL INGREDIENT AND KEY STARTING MATERIAL SUPPLIERS

4.5.2 ESTABLISHMENT OF REGIONAL PHARMACEUTICAL MANUFACTURING AND PRODUCTION HUBS

4.5.3 STRATEGIC STOCKPILING OF CRITICAL APIS, INTERMEDIATES, AND ESSENTIAL MEDICINES

4.5.4 DEVELOPMENT OF ALTERNATIVE PHARMACEUTICAL LOGISTICS AND COLD CHAIN ROUTES

4.5.5 STRATEGIC PARTNERSHIPS WITH CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS)

4.5.6 ENERGY & MANUFACTURING OPERATIONAL COST RISK

4.5.6.1 RISING ENERGY COSTS IN PHARMACEUTICAL AND MANUFACTURING FACILITIES

4.5.6.2 INCREASED COSTS FOR RAW MATERIALS, SOLVENTS, AND CHEMICAL INTERMEDIATES

4.5.6.3 ADOPTION OF ENERGY-EFFICIENT PHARMACEUTICAL MANUFACTURING TECHNOLOGIES

4.5.7 GEOGRAPHIC FOOTPRINT REASSESSMENT

4.5.7.1 EXPANSION OF PHARMACEUTICAL MANUFACTURING IN POLITICALLY STABLE REGIONS

4.5.7.2 DIVERSIFICATION OF EUROPE API AND DRUG MANUFACTURING BASES

4.5.8 SCENARIO PLANNING & RISK MANAGEMENT

4.5.8.1 DEVELOPMENT OF PHARMACEUTICAL SUPPLY CHAIN CONTINGENCY PLANS

4.5.9 CASH & FINANCIAL PROTECTION

4.5.9.1 INVESTMENTS IN DOMESTIC API AND DRUG MANUFACTURING INFRASTRUCTURE

4.5.10 DATA PROTECTION

4.5.10.1 PROTECTION OF CLINICAL TRIAL DATA, PATIENT DATA, AND DRUG DEVELOPMENT INFORMATION

4.5.10.2 NEW BUSINESS AND EMERGING REVENUE OPPORTUNITIES & FUTURE OUTLOOK

4.6 PATENT ANALYSIS

4.6.1 DRUG

4.6.1.1 BRAND NAME

4.6.1.2 GENERIC NAME

4.6.2 THERAPEUTIC INDICATION

4.6.3 PHARMACOLOGICAL CLASS OF THE DRUG

4.6.4 DRUG PRIMARY INDICATION

4.6.5 MARKET STATUS

4.6.6 MEDICATION TYPE

4.6.7 DRUG DOSAGE FORM

4.6.8 DOSAGE AVAILABILITY

4.6.9 PACKAGING TYPE

4.6.10 DRUG ROUTE OF ADMINISTRATION

4.6.11 DOSING FREQUENCY

4.6.12 DRUG INSIGHT

4.7 PATENT ANALYSIS

4.7.1 PATENT FILING LANDSCAPE

4.7.2 GEOGRAPHIC DISTRIBUTION OF PATENT FILINGS

4.7.3 KEY PATENT APPLICANTS AND ASSIGNEES

4.7.4 INVENTOR LANDSCAPE AND RESEARCH CONTRIBUTION

4.7.5 IPC CODE ANALYSIS

4.7.6 PUBLICATION TREND ANALYSIS

4.7.7 COMPETITIVE PATENT INTENSITY AND FUTURE OUTLOOK

4.8 PIPELINE ANALYSIS:

4.8.1 CLINICAL TRIALS AND PHASE ANALYSIS

4.8.2 DRUG THERAPY PIPELINE

4.8.3 PHASE III CANDIDATES

4.8.4 PHASE II CANDIDATES

4.8.5 PHASE I CANDIDATES

4.8.6 OTHERS (PRE-CLINICAL AND RESEARCH)

4.9 R&D ANALYSIS

4.9.1 COMPARATIVE ANALYS

4.9.2 DRUG DEVELOPMENTAL LANDSCAPE

4.9.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

4.9.4 THERAPEUTIC ASSESSMENT

4.9.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

5 HEALTHCARE TARIFFS IMPACT ANALYSIS

5.1 OVERVIEW

5.2 TARIFF STRUCTURES

5.2.1 EUROPE VS. REGIONAL TARIFF STRUCTURES

5.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS

5.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS, REIMBURSEMENT POLICIES

5.2.4 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION

5.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS

5.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS

5.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS

5.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS

5.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS

5.4.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES

5.4.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE

5.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS

5.5.1 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN

5.5.2 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS

5.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY

5.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR

6 REGULATORY FRAMEWORK

6.1 REGULATORY APPROVAL PROCESS

6.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

6.3 REGULATORY APPROVAL PATHWAYS

6.4 LICENSING AND REGISTRATION

6.5 POST-MARKETING SURVEILLANCE (PMS)

6.6 GOOD MANUFACTURING PRACTICES (GMP) GUIDELINES

7 MARKET OVERVIEW

7.1 DRIVER

7.1.1 ADVANCEMENTS IN GENETIC DIAGNOSTICS AND NEXT-GENERATION SEQUENCING

7.1.2 INCREASING INVESTMENT IN RARE DISEASE AND ORPHAN DRUG RESEARCH

7.1.3 CLINICAL AWARENESS AND IMPROVED NEONATAL SCREENING

7.1.4 GROWING DEMAND FOR ADVANCED SUPPORTIVE CARE AND LONG-TERM PATIENT MANAGEMENT

7.2 RESTRAINTS

7.2.1 EXTREMELY LOW DISEASE PREVALENCE OF MVID

7.2.2 HIGH COST OF TREATMENT (ESPECIALLY TPN AND TRANSPLANTATION)

7.3 OPPORTUNITY

7.3.1 EMERGENCE OF GENE THERAPY TARGETING MYO5B MUTATIONS

7.3.2 ADVANCEMENTS IN ORGANOID-BASED AND STEM CELL THERAPIES

7.3.3 COLLABORATIONS BETWEEN RESEARCH INSTITUTES AND PHARMA COMPANIES

7.4 CHALLENGES

7.4.1 HIGH RISK ASSOCIATED WITH TRANSPLANT PROCEDURES

7.4.2 DIFFICULTIES IN CONDUCTING CLINICAL TRIALS

8 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION

8.1 OVERVIEW

8.2 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

8.2.1 EARLY-ONSET (CONGENITAL) MVID

8.2.2 GENETIC SUBTYPES

8.2.3 NON-SYNDROMIC MVID

8.2.4 SYNDROMIC MVID

8.2.5 LATE-ONSET / ATYPICAL MVID

8.3 EUROPE EARLY-ONSET (CONGENITAL) MVID IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.3.1 NORTH AMERICA

8.3.2 EUROPE

8.3.3 ASIA-PACIFIC

8.3.4 MIDDLE EAST AND AFRICA

8.3.5 SOUTH AMERICA

8.4 EUROPE GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.4.1 MYO5B MUTATION-ASSOCIATED MVID

8.4.2 STX3 MUTATION-ASSOCIATED MVID

8.4.3 STXBP2 MUTATION-ASSOCIATED MVID

8.4.4 OTHER RARE GENETIC VARIANTS

8.4.5 UNC45A MUTATION-ASSOCIATED MVID

8.5 EUROPE GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.5.1 NORTH AMERICA

8.5.2 EUROPE

8.5.3 ASIA-PACIFIC

8.5.4 MIDDLE EAST AND AFRICA

8.5.5 SOUTH AMERICA

8.6 EUROPE NON-SYNDROMIC MVID IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.6.1 NORTH AMERICA

8.6.2 EUROPE

8.6.3 ASIA-PACIFIC

8.6.4 MIDDLE EAST AND AFRICA

8.6.5 SOUTH AMERICA

8.7 EUROPE SYNDROMIC MVID IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.7.1 NORTH AMERICA

8.7.2 EUROPE

8.7.3 ASIA-PACIFIC

8.7.4 MIDDLE EAST AND AFRICA

8.7.5 SOUTH AMERICA

8.8 EUROPE LATE-ONSET / ATYPICAL MVID IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.8.1 NORTH AMERICA

8.8.2 EUROPE

8.8.3 ASIA-PACIFIC

8.8.4 MIDDLE EAST AND AFRICA

8.8.5 SOUTH AMERICA

9 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE

9.1 OVERVIEW

9.2 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

9.2.1 NUTRITIONAL SUPPORT

9.2.2 SURGICAL & ADVANCED INTERVENTIONS

9.2.3 PHARMACOLOGICAL MANAGEMENT

9.2.4 EMERGING & PIPELINE THERAPIES

9.3 EUROPE NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.3.1 NORTH AMERICA

9.3.2 EUROPE

9.3.3 ASIA-PACIFIC

9.3.4 MIDDLE EAST AND AFRICA

9.3.5 SOUTH AMERICA

9.4 EUROPE NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.4.1 SPECIALIZED PEDIATRIC NUTRITIONAL FORMULATIONS

9.4.2 ENTERAL NUTRITION (MINIMAL / ADJUNCT)

9.5 EUROPE TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.5.1 OTHERS (AMINO ACIDS, LIPIDS, GLUCOSE, ELECTROLYTES, VITAMINS, TRACE ELEMENTS)

9.5.2 GLUTAMINE

9.6 EUROPE SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.6.1 INTESTINAL TRANSPLANTATION

9.6.2 COMBINED LIVER-INTESTINAL TRANSPLANT

9.6.3 OTHERS

9.7 EUROPE SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.7.1 NORTH AMERICA

9.7.2 EUROPE

9.7.3 ASIA-PACIFIC

9.7.4 MIDDLE EAST AND AFRICA

9.7.5 SOUTH AMERICA

9.8 EUROPE PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.8.1 ELECTROLYTE REPLACEMENT THERAPIES

9.8.2 ANTIBIOTICS (INFECTION CONTROL)

9.8.3 HEPATOPROTECTIVE AGENTS (TPN-INDUCED LIVER DISEASE)

9.8.4 ANTI-DIARRHEAL AGENTS

9.8.5 ANTI-SECRETORY AGENTS

9.8.6 OTHERS

9.9 EUROPE PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.9.1 NORTH AMERICA

9.9.2 EUROPE

9.9.3 ASIA-PACIFIC

9.9.4 MIDDLE EAST AND AFRICA

9.9.5 SOUTH AMERICA

9.1 EUROPE ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.10.1 OCTREOTIDE

9.10.2 SOMATOSTATIN

9.10.3 LOPERAMIDE

9.10.4 CHLORPROMAZINE

9.10.5 OTHERS

9.11 EUROPE PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

9.11.1 GENERICS

9.11.2 BRANDED

9.12 EUROPE BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.12.1 SANDOSTATIN

9.12.2 IMODIUM

9.12.3 MYCAPSSA

9.12.4 BYNFEZIA

9.12.5 DIAMODE

9.12.6 OTHERS

9.13 EUROPE EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.13.1 GENE THERAPY (MYO5B CORRECTION)

9.13.2 STEM CELL THERAPY

9.13.3 ORGANOID-BASED THERAPIES

9.13.4 PRECISION MEDICINE / TARGETED MOLECULAR THERAPY

9.14 EUROPE EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.14.1 NORTH AMERICA

9.14.2 EUROPE

9.14.3 ASIA-PACIFIC

9.14.4 MIDDLE EAST AND AFRICA

9.14.5 SOUTH AMERICA

10 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

10.2.1 INTRAVENOUS (IV)

10.2.2 ORAL

10.2.3 SUBCUTANEOUS

10.2.4 ENTERAL

10.2.5 OTHERS

10.3 EUROPE INTRAVENOUS (IV) IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.3.1 NORTH AMERICA

10.3.2 EUROPE

10.3.3 ASIA-PACIFIC

10.3.4 MIDDLE EAST AND AFRICA

10.3.5 SOUTH AMERICA

10.4 EUROPE ORAL IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.4.1 NORTH AMERICA

10.4.2 EUROPE

10.4.3 ASIA-PACIFIC

10.4.4 MIDDLE EAST AND AFRICA

10.4.5 SOUTH AMERICA

10.5 EUROPE SUBCUTANEOUS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.5.1 NORTH AMERICA

10.5.2 EUROPE

10.5.3 ASIA-PACIFIC

10.5.4 MIDDLE EAST AND AFRICA

10.5.5 SOUTH AMERICA

10.6 EUROPE ENTERAL IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.6.1 NORTH AMERICA

10.6.2 EUROPE

10.6.3 ASIA-PACIFIC

10.6.4 MIDDLE EAST AND AFRICA

10.6.5 SOUTH AMERICA

10.7 EUROPE OTHERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.7.1 NORTH AMERICA

10.7.2 EUROPE

10.7.3 ASIA-PACIFIC

10.7.4 MIDDLE EAST AND AFRICA

10.7.5 SOUTH AMERICA

11 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE

11.1 OVERVIEW

11.2 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

11.2.1 GENETIC TESTING

11.2.2 DEFINITIVE DIAGNOSTICS

11.2.3 LABORATORY TESTING

11.2.4 IMAGING & SUPPORT DIAGNOSTICS

11.3 EUROPE GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.3.1 NORTH AMERICA

11.3.2 EUROPE

11.3.3 ASIA-PACIFIC

11.3.4 MIDDLE EAST AND AFRICA

11.3.5 SOUTH AMERICA

11.4 EUROPE GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

11.4.1 POSTNATAL GENETIC TESTING

11.4.2 PRENATAL GENETIC SCREENING

11.4.3 CARRIER SCREENING

11.4.4 OTHERS

11.5 EUROPE DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

11.5.1 SMALL INTESTINAL BIOPSY

11.5.2 ELECTRON MICROSCOPY

11.5.3 OTHERS

11.6 EUROPE DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.6.1 NORTH AMERICA

11.6.2 EUROPE

11.6.3 ASIA-PACIFIC

11.6.4 MIDDLE EAST AND AFRICA

11.6.5 SOUTH AMERICA

11.7 EUROPE LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

11.7.1 ELECTROLYTE PANELS

11.7.2 STOOL ANALYSIS

11.7.3 NUTRITIONAL DEFICIENCY TESTING

11.7.4 OTHERS

11.8 EUROPE LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.8.1 NORTH AMERICA

11.8.2 EUROPE

11.8.3 ASIA-PACIFIC

11.8.4 MIDDLE EAST AND AFRICA

11.8.5 SOUTH AMERICA

12 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY END USER

12.1 OVERVIEW

12.2 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

12.2.1 HOSPITALS

12.2.2 PEDIATRIC SPECIALTY CLINICS

12.2.3 HOME HEALTHCARE SETTINGS (TPN ADMINISTRATION)

12.2.4 TRANSPLANT CENTERS

12.2.5 RESEARCH INSTITUTES & ACADEMIC CENTERS

12.2.6 OTHERS

12.3 EUROPE HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.3.1 NORTH AMERICA

12.3.2 EUROPE

12.3.3 ASIA-PACIFIC

12.3.4 MIDDLE EAST AND AFRICA

12.3.5 SOUTH AMERICA

12.4 EUROPE HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

12.4.1 PUBLIC HOSPITALS

12.4.2 PRIVATE HOSPITALS

12.5 EUROPE PEDIATRIC SPECIALTY CLINICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.5.1 NORTH AMERICA

12.5.2 EUROPE

12.5.3 ASIA-PACIFIC

12.5.4 MIDDLE EAST AND AFRICA

12.5.5 SOUTH AMERICA

12.6 EUROPE HOME HEALTHCARE SETTINGS (TPN ADMINISTRATION) IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.6.1 NORTH AMERICA

12.6.2 EUROPE

12.6.3 ASIA-PACIFIC

12.6.4 MIDDLE EAST AND AFRICA

12.6.5 SOUTH AMERICA

12.7 EUROPE TRANSPLANT CENTERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.7.1 NORTH AMERICA

12.7.2 EUROPE

12.7.3 ASIA-PACIFIC

12.7.4 MIDDLE EAST AND AFRICA

12.7.5 SOUTH AMERICA

12.8 EUROPE RESEARCH INSTITUTES & ACADEMIC CENTERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.8.1 NORTH AMERICA

12.8.2 EUROPE

12.8.3 ASIA-PACIFIC

12.8.4 MIDDLE EAST AND AFRICA

12.8.5 SOUTH AMERICA

12.9 EUROPE OTHERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.9.1 NORTH AMERICA

12.9.2 EUROPE

12.9.3 ASIA-PACIFIC

12.9.4 MIDDLE EAST AND AFRICA

12.9.5 SOUTH AMERICA

13 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS

13.1 OVERVIEW

13.2 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

13.2.1 NEONATES

13.2.2 INFANTS

13.2.3 PEDIATRIC (LONG-TERM SURVIVORS)

13.3 EUROPE NEONATES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

13.3.1 NORTH AMERICA

13.3.2 EUROPE

13.3.3 ASIA-PACIFIC

13.3.4 MIDDLE EAST AND AFRICA

13.3.5 SOUTH AMERICA

13.4 EUROPE INFANTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

13.4.1 NORTH AMERICA

13.4.2 EUROPE

13.4.3 ASIA-PACIFIC

13.4.4 MIDDLE EAST AND AFRICA

13.4.5 SOUTH AMERICA

13.5 EUROPE PEDIATRIC (LONG-TERM SURVIVORS) IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

13.5.1 NORTH AMERICA

13.5.2 EUROPE

13.5.3 ASIA-PACIFIC

13.5.4 MIDDLE EAST AND AFRICA

13.5.5 SOUTH AMERICA

14 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

14.2.1 HOSPITAL PHARMACIES

14.2.2 SPECIALTY PHARMACIES

14.2.3 DIRECT PROCUREMENT

14.2.4 ONLINE PHARMACIES

14.2.5 OTHERS

14.3 EUROPE HOSPITAL PHARMACIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.3.1 NORTH AMERICA

14.3.2 EUROPE

14.3.3 ASIA-PACIFIC

14.3.4 MIDDLE EAST AND AFRICA

14.3.5 SOUTH AMERICA

14.4 EUROPE SPECIALTY PHARMACIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.4.1 NORTH AMERICA

14.4.2 EUROPE

14.4.3 ASIA-PACIFIC

14.4.4 MIDDLE EAST AND AFRICA

14.4.5 SOUTH AMERICA

14.5 EUROPE DIRECT PROCUREMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.5.1 NORTH AMERICA

14.5.2 EUROPE

14.5.3 ASIA-PACIFIC

14.5.4 MIDDLE EAST AND AFRICA

14.5.5 SOUTH AMERICA

14.6 EUROPE ONLINE PHARMACIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.6.1 NORTH AMERICA

14.6.2 EUROPE

14.6.3 ASIA-PACIFIC

14.6.4 MIDDLE EAST AND AFRICA

14.6.5 SOUTH AMERICA

14.7 EUROPE OTHERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.7.1 NORTH AMERICA

14.7.2 EUROPE

14.7.3 ASIA-PACIFIC

14.7.4 MIDDLE EAST AND AFRICA

14.7.5 SOUTH AMERICA

15 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY REGION

15.1 EUROPE

15.1.1 GERMANY

15.1.2 U.K.

15.1.3 FRANCE

15.1.4 ITALY

15.1.5 SPAIN

15.1.6 SWITZERLAND

15.1.7 NETHERLANDS

15.1.8 BELGIUM

15.1.9 TURKEY

15.1.10 RUSSIA

15.1.11 DENMARK

15.1.12 SWEDEN

15.1.13 NORWAY

15.1.14 FINLAND

15.1.15 REST OF EUROPE

16 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: COMPANY LANDSCAPE

16.1 MANUFACTURER COMPANY SHARE ANALYSIS: GLOBAL

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 BAXTER INTERNATIONAL INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENT

18.2 FRESENIUS SE & CO. KGAA

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENT

18.3 B BRAUN SE

18.3.1 COMPANY SNAPSHOT

18.3.2 COMPANY SHARE ANALYSIS

18.3.3 PRODUCT PORTFOLIO

18.3.4 RECENT DEVELOPMENT

18.4 NESTLÉ HEALTH SCIENCE

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 NUTRICIA (DANONE GROUP)

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 ABBOTT LABORATORIES

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 ACULIFE HEALTHCARE PVT. LTD.

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENT

18.8 AJINOMOTO CAMBROOKE, INC

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 CHIESI FARMACEUTICI S.P.A.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENT

18.1 EMYRIS BIOLIFESCIENCES

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 FUNCTIONAL FORMULARIES.

18.11.1 COMPANY SNAPSHOT

18.11.2 PRODUCT PORTFOLIO

18.11.3 RECENT DEVELOPMENT

18.12 GEDEON RICHTER PLC.

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 HEXAGON NUTRITION LTD.

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENT

18.14 IPSEN S.A.

18.14.1 COMPANY SNAPSHOT

18.14.2 REVENUE ANALYSIS

18.14.3 PRODUCT PORTFOLIO

18.14.4 RECENT DEVELOPMENT

18.15 NAPO PHARMACEUTICALS (PART OF JAGUAR HEALTH, INC)

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 KATE FARMS

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 KENVUE

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 PRODUCT PORTFOLIO

18.17.4 RECENT DEVELOPMENT

18.18 LABORATOIRE AGUETTANT

18.18.1 COMPANY SNAPSHOT

18.18.2 PRODUCT PORTFOLIO

18.18.3 RECENT DEVELOPMENT

18.19 LUOXIN PHARMACEUTICALS GROUP STOCK COLTD

18.19.1 COMPANY SNAPSHOT

18.19.2 REVENUE ANALYSIS

18.19.3 PRODUCT PORTFOLIO

18.19.4 RECENT DEVELOPMENT

18.2 NOVARTIS AG

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENT

18.21 NOVUS LIFESCIENCES PVT. LTD.

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENT

18.22 NUTRISENS MEDICAL ITALIA

18.22.1 COMPANY SNAPSHOT

18.22.2 PRODUCT PORTFOLIO

18.22.3 RECENT DEVELOPMENT

18.23 OSCAR REMEDIES PRIVATE LIMITED

18.23.1 COMPANY SNAPSHOT

18.23.2 PRODUCT PORTFOLIO

18.23.3 RECENT DEVELOPMENT

18.24 OTSUKA PHARMACEUTICAL INDIA PRIVATE LIMITED

18.24.1 COMPANY SNAPSHOT

18.24.2 PRODUCT PORTFOLIO

18.24.3 RECENT DEVELOPMENT

18.25 PENTAGON LABS LTD

18.25.1 COMPANY SNAPSHOT

18.25.2 PRODUCT PORTFOLIO

18.25.3 RECENT DEVELOPMENT

18.26 PFIZER INC.

18.26.1 COMPANY SNAPSHOT

18.26.2 REVENUE ANALYSIS

18.26.3 PRODUCT PORTFOLIO

18.26.4 RECENT DEVELOPMENT

18.27 PHEBRA PTY LTD

18.27.1 COMPANY SNAPSHOT

18.27.2 PRODUCT PORTFOLIO

18.27.3 RECENT DEVELOPMENT

18.28 PRISTINE ORGANICS PVT LTD.

18.28.1 COMPANY SNAPSHOT

18.28.2 PRODUCT PORTFOLIO

18.28.3 RECENT DEVELOPMENT

18.29 SICHUAN KELUN PHARMACEUTICAL CO., LTD.

18.29.1 COMPANY SNAPSHOT

18.29.2 REVENUE ANALYSIS

18.29.3 PRODUCT PORTFOLIO

18.29.4 RECENT DEVELOPMENT

18.3 SUN PHARMACEUTICAL INDUSTRIES LTD.

18.30.1 COMPANY SNAPSHOT

18.30.2 REVENUE ANALYSIS

18.30.3 PRODUCT PORTFOLIO

18.30.4 RECENT DEVELOPMENTS

18.31 TEVA PHARMACEUTICAL INDUSTRIES LTD.

18.31.1 COMPANY SNAPSHOT

18.31.2 REVENUE ANALYSIS

18.31.3 PRODUCT PORTFOLIO

18.31.4 RECENT DEVELOPMENT

18.32 USV PRIVATE LIMITED

18.32.1 COMPANY SNAPSHOT

18.32.2 PRODUCT PORTFOLIO

18.32.3 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

List of Table

TABLE 1 MVID INCIDENCE BY GENDER

TABLE 2 MVID TREATMENT RATE

TABLE 3 MVID MORTALITY RATE

TABLE 4 MVID TREATMENT

TABLE 5 PATIENT TREATMENT SUCCESS RATE

TABLE 6 KEY REGULATORY MILESTONES FOR CROFELEMER IN MVID DEVELOPMENT

TABLE 7 COMPARATIVE REGULATORY APPROVAL ENVIRONMENT FOR ORPHAN DRUGS BY GEOGRAPHY

TABLE 8 APPLICABLE EXPEDITED REGULATORY PATHWAYS FOR MVID THERAPEUTICS

TABLE 9 CURRENT LICENSING AND REGISTRATION STATUS OF MVID THERAPEUTICS

TABLE 10 POST-MARKETING SURVEILLANCE REQUIREMENTS FOR ORPHAN DRUGS

TABLE 11 GMP AND QUALITY COMPLIANCE GUIDELINES RELEVANT TO MVID DRUG DEVELOPMENT

TABLE 12 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 13 EUROPE EARLY-ONSET (CONGENITAL) MVID IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 14 EUROPE GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 15 EUROPE GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 16 EUROPE NON-SYNDROMIC MVID IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 17 EUROPE SYNDROMIC MVID IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 18 EUROPE LATE-ONSET / ATYPICAL MVID IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 19 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 20 EUROPE NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 21 EUROPE NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 22 EUROPE TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 23 EUROPE SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 24 EUROPE SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 25 EUROPE PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 26 EUROPE PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 27 EUROPE ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 28 EUROPE PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 29 EUROPE BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 30 EUROPE EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 31 EUROPE EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 32 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 33 EUROPE INTRAVENOUS (IV) IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 34 EUROPE ORAL IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 35 EUROPE SUBCUTANEOUS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 36 EUROPE ENTERAL IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 37 EUROPE OTHERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 38 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 39 EUROPE GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 40 EUROPE GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 41 EUROPE DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 42 EUROPE DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 43 EUROPE LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 44 EUROPE LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 45 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 46 EUROPE HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 47 EUROPE HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 48 EUROPE PEDIATRIC SPECIALTY CLINICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 49 EUROPE HOME HEALTHCARE SETTINGS (TPN ADMINISTRATION) IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 50 EUROPE TRANSPLANT CENTERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 51 EUROPE RESEARCH INSTITUTES & ACADEMIC CENTERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 52 EUROPE OTHERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 53 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 54 EUROPE NEONATES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 55 EUROPE INFANTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 56 EUROPE PEDIATRIC (LONG-TERM SURVIVORS) IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 57 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 58 EUROPE HOSPITAL PHARMACIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 59 EUROPE SPECIALTY PHARMACIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 60 EUROPE DIRECT PROCUREMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 61 EUROPE ONLINE PHARMACIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 62 EUROPE OTHERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 63 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, 2018-2033 (USD THOUSAND)

TABLE 64 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 65 USD THOUSAND

TABLE 66 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 67 EUROPE GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 68 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 69 EUROPE NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 70 EUROPE TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 71 EUROPE SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 72 EUROPE PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 73 EUROPE ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 74 EUROPE PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 75 EUROPE BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 76 EUROPE EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 77 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 78 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 79 EUROPE GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 80 EUROPE DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 81 EUROPE LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 82 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 83 EUROPE HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 84 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 85 EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 86 GERMANY MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 87 GERMANY GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 88 GERMANY MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 89 GERMANY NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 90 GERMANY TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 91 GERMANY SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 92 GERMANY PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 93 GERMANY ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 94 GERMANY PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 95 GERMANY BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 96 GERMANY EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 97 GERMANY MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 98 GERMANY MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 99 GERMANY GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 100 GERMANY DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 101 GERMANY LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 102 GERMANY MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 103 GERMANY HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 104 GERMANY MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 105 GERMANY MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 106 U.K. MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 107 U.K. GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 108 U.K. MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 109 U.K. NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 110 U.K. TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 111 U.K. SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 112 U.K. PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 113 U.K. ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 114 U.K. PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 115 U.K. BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 116 U.K. EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 117 U.K. MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 118 U.K. MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 119 U.K. GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 120 U.K. DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 121 U.K. LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 122 U.K. MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 123 U.K. HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 124 U.K. MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 125 U.K. MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 126 FRANCE MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 127 FRANCE GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 128 FRANCE MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 129 FRANCE NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 130 FRANCE TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 131 FRANCE SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 132 FRANCE PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 133 FRANCE ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 134 FRANCE PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 135 FRANCE BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 136 FRANCE EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 137 FRANCE MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 138 FRANCE MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 139 FRANCE GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 140 FRANCE DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 141 FRANCE LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 142 FRANCE MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 143 FRANCE HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 144 FRANCE MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 145 FRANCE MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 146 ITALY MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 147 ITALY GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 148 ITALY MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 149 ITALY NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 150 ITALY TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 151 ITALY SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 152 ITALY PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 153 ITALY ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 154 ITALY PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 155 ITALY BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 156 ITALY EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 157 ITALY MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 158 ITALY MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 159 ITALY GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 160 ITALY DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 161 ITALY LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 162 ITALY MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 163 ITALY HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 164 ITALY MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 165 ITALY MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 166 SPAIN MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 167 SPAIN GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 168 SPAIN MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 169 SPAIN NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 170 SPAIN TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 171 SPAIN SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 172 SPAIN PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 173 SPAIN ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 174 SPAIN PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 175 SPAIN BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 176 SPAIN EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 177 SPAIN MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 178 SPAIN MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 179 SPAIN GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 180 SPAIN DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 181 SPAIN LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 182 SPAIN MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 183 SPAIN HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 184 SPAIN MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 185 SPAIN MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 186 SWITZERLAND MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 187 SWITZERLAND GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 188 SWITZERLAND MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 189 SWITZERLAND NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 190 SWITZERLAND TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 191 SWITZERLAND SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 192 SWITZERLAND PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 193 SWITZERLAND ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 194 SWITZERLAND PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 195 SWITZERLAND BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 196 SWITZERLAND EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 197 SWITZERLAND MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 198 SWITZERLAND MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 199 SWITZERLAND GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 200 SWITZERLAND DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 201 SWITZERLAND LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 202 SWITZERLAND MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 203 SWITZERLAND HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 204 SWITZERLAND MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 205 SWITZERLAND MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 206 NETHERLANDS MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 207 NETHERLANDS GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 208 NETHERLANDS MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 209 NETHERLANDS NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 210 NETHERLANDS TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 211 NETHERLANDS SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 212 NETHERLANDS PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 213 NETHERLANDS ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 214 NETHERLANDS PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 215 NETHERLANDS BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 216 NETHERLANDS EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 217 NETHERLANDS MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 218 NETHERLANDS MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 219 NETHERLANDS GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 220 NETHERLANDS DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 221 NETHERLANDS LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 222 NETHERLANDS MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 223 NETHERLANDS HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 224 NETHERLANDS MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 225 NETHERLANDS MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 226 BELGIUM MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 227 BELGIUM GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 228 BELGIUM MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 229 BELGIUM NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 230 BELGIUM TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 231 BELGIUM SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 232 BELGIUM PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 233 BELGIUM ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 234 BELGIUM PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 235 BELGIUM BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 236 BELGIUM EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 237 BELGIUM MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 238 BELGIUM MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 239 BELGIUM GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 240 BELGIUM DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 241 BELGIUM LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 242 BELGIUM MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 243 BELGIUM HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 244 BELGIUM MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 245 BELGIUM MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 246 TURKEY MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 247 TURKEY GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 248 TURKEY MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 249 TURKEY NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 250 TURKEY TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 251 TURKEY SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 252 TURKEY PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 253 TURKEY ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 254 TURKEY PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 255 TURKEY BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 256 TURKEY EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 257 TURKEY MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 258 TURKEY MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 259 TURKEY GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 260 TURKEY DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 261 TURKEY LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 262 TURKEY MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 263 TURKEY HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 264 TURKEY MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 265 TURKEY MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 266 RUSSIA MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 267 RUSSIA GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 268 RUSSIA MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 269 RUSSIA NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 270 RUSSIA TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 271 RUSSIA SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 272 RUSSIA PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 273 RUSSIA ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 274 RUSSIA PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 275 RUSSIA BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 276 RUSSIA EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 277 RUSSIA MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 278 RUSSIA MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 279 RUSSIA GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 280 RUSSIA DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 281 RUSSIA LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 282 RUSSIA MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 283 RUSSIA HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 284 RUSSIA MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 285 RUSSIA MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 286 DENMARK MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 287 DENMARK GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 288 DENMARK MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 289 DENMARK NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 290 DENMARK TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 291 DENMARK SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 292 DENMARK PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 293 DENMARK ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 294 DENMARK PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 295 DENMARK BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 296 DENMARK EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 297 DENMARK MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 298 DENMARK MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 299 DENMARK GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 300 DENMARK DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 301 DENMARK LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 302 DENMARK MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 303 DENMARK HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 304 DENMARK MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 305 DENMARK MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 306 SWEDEN MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 307 SWEDEN GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 308 SWEDEN MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 309 SWEDEN NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 310 SWEDEN TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 311 SWEDEN SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 312 SWEDEN PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 313 SWEDEN ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 314 SWEDEN PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 315 SWEDEN BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 316 SWEDEN EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 317 SWEDEN MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 318 SWEDEN MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 319 SWEDEN GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 320 SWEDEN DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 321 SWEDEN LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 322 SWEDEN MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 323 SWEDEN HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 324 SWEDEN MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 325 SWEDEN MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 326 NORWAY MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 327 NORWAY GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 328 NORWAY MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 329 NORWAY NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 330 NORWAY TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 331 NORWAY SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 332 NORWAY PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 333 NORWAY ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 334 NORWAY PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 335 NORWAY BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 336 NORWAY EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 337 NORWAY MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 338 NORWAY MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 339 NORWAY GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 340 NORWAY DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 341 NORWAY LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 342 NORWAY MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 343 NORWAY HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 344 NORWAY MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 345 NORWAY MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 346 FINLAND MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 347 FINLAND GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 348 FINLAND MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 349 FINLAND NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 350 FINLAND TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 351 FINLAND SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 352 FINLAND PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 353 FINLAND ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 354 FINLAND PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 355 FINLAND BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 356 FINLAND EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 357 FINLAND MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 358 FINLAND MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 359 FINLAND GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 360 FINLAND DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 361 FINLAND LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 362 FINLAND MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 363 FINLAND HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 364 FINLAND MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 365 FINLAND MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 366 REST OF EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

TABLE 367 REST OF EUROPE GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 368 REST OF EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 369 REST OF EUROPE NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 370 REST OF EUROPE TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 371 REST OF EUROPE SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 372 REST OF EUROPE PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 373 REST OF EUROPE ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 374 REST OF EUROPE PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

TABLE 375 REST OF EUROPE BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 376 REST OF EUROPE EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 377 REST OF EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 378 REST OF EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

TABLE 379 REST OF EUROPE GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 380 REST OF EUROPE DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 381 REST OF EUROPE LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 382 REST OF EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 383 REST OF EUROPE HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 384 REST OF EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

TABLE 385 REST OF EUROPE MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

List of Figure

FIGURE 1 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: SEGMENTATION

FIGURE 2 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: DROC ANALYSIS

FIGURE 4 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: EUROPE VS REGIONAL ANALYSIS

FIGURE 5 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 EUROPE MICROVILLUS INCLUSION DISEASE MARKET : VENDOR SHARE ANALYSIS

FIGURE 10 EXECUTIVE SUMMARY

FIGURE 11 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: SEGMENTATION

FIGURE 12 ADVANCEMENTS IN GENETIC DIAGNOSTICS AND NEXT-GENERATION SEQUENCING EXPECTED TO DRIVE THE EUROPE MICROVILLUS INCLUSION DISEASE MARKET IN THE FORECAST PERIOD OF 2026 TO 2033

FIGURE 13 EARLY-ONSET (CONGENITAL) MVID SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MICROVILLUS INCLUSION DISEASE MARKET IN 2026 & 2033

FIGURE 14 GEOGRAPHIC DISTRIBUTION OF PATENT FILINGS

FIGURE 15 KEY PATENT APPLICANTS

FIGURE 16 NUMBER OF PATENT PER IPC CODE

FIGURE 17 NUMBER OF PATENT PER YEAR

FIGURE 18 DROC ANALYSIS

FIGURE 19 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY DISEASE TYPE / CLINICAL PRESENTATION, 2025

FIGURE 20 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY DISEASE TYPE / CLINICAL PRESENTATION, 2026 TO 2033 (USD MILLION)

FIGURE 21 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY DISEASE TYPE / CLINICAL PRESENTATION, CAGR (2026- 2033)

FIGURE 22 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY DISEASE TYPE / CLINICAL PRESENTATION, LIFELINE CURVE

FIGURE 23 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY TREATMENT TYPE, 2025

FIGURE 24 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY TREATMENT TYPE, 2026 TO 2033 (USD MILLION)

FIGURE 25 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY TREATMENT TYPE, CAGR (2026- 2033)

FIGURE 26 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 27 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2025

FIGURE 28 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2026 TO 2033 (USD MILLION)

FIGURE 29 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2026- 2033)

FIGURE 30 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 31 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY DIAGNOSIS TYPE, 2025

FIGURE 32 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY DIAGNOSIS TYPE, 2026 TO 2033 (USD MILLION)

FIGURE 33 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY DIAGNOSIS TYPE, CAGR (2026- 2033)

FIGURE 34 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY DIAGNOSIS TYPE, LIFELINE CURVE

FIGURE 35 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY END USER, 2025

FIGURE 36 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY END USER, 2026 TO 2033 (USD MILLION)

FIGURE 37 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY END USER, CAGR (2026- 2033)

FIGURE 38 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY END USER, LIFELINE CURVE

FIGURE 39 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY PATIENT DEMOGRAPHICS, 2025

FIGURE 40 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY PATIENT DEMOGRAPHICS, 2026 TO 2033 (USD MILLION)

FIGURE 41 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2026- 2033)

FIGURE 42 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE

FIGURE 43 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2025

FIGURE 44 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2026 TO 2033 (USD MILLION)

FIGURE 45 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2026- 2033)

FIGURE 46 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: SNAPSHOT (2025)

FIGURE 48 EUROPE MICROVILLUS INCLUSION DISEASE MARKET: COMPANY SHARE 2025 (%)

View Detailed Information

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

What is the current market size of the Europe Microvillus Inclusion Disease Market?

The Europe Microvillus Inclusion Disease Market size was USD 492.79 million in 2025.

What is the expected growth rate of Europe Microvillus Inclusion Disease Market?

The Europe is expected to grow at a CAGR of 3.8% from 2026 to 2033, fueled by improving healthcare accessibility, increasing awareness of rare gastrointestinal disorders, and growing investments in advanced treatment options across emerging economies.

Which Country dominate the Europe Microvillus Inclusion Disease Market?

The Germany dominates the Europe Microvillus Inclusion Disease Market, accounting for approximately 16.21% of the regional share in 2025. The country’s leadership is supported by advanced healthcare infrastructure, widespread availability of genetic testing technologies, and strong research activities focused on rare pediatric disorders. Increasing awareness regarding congenital gastrointestinal diseases and the presence of specialized neonatal and pediatric care centers are further driving market growth. Additionally, favorable reimbursement policies, growing investments in orphan drug development, and high adoption of advanced nutritional support therapies continue to strengthen the market position.

Which country is the fastest growing in the Europe Microvillus Inclusion Disease Market?

Netherlands is the fastest-growing country in the Europe Microvillus Inclusion Disease Market, projected to register a CAGR of 4.5% during the forecast period. Growth is driven by rapid improvements in healthcare infrastructure, increasing healthcare expenditure, and rising awareness regarding rare genetic and pediatric disorders. Expanding access to advanced diagnostic technologies, including next-generation sequencing and molecular testing, is supporting early disease identification and treatment planning.

Industry Related Reports